Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Child and Adolescent Psychiatry and Mental Health
Published in: Child and Adolescent Psychiatry and Mental Health 1/2015

Open Access 01-12-2015 | Review

Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway

Authors: David Coghill, Sarah Seth

Published in: Child and Adolescent Psychiatry and Mental Health | Issue 1/2015

Login to get access

Abstract

Attention-deficit/hyperactivity disorder (ADHD) has become a major aspect of the work of child and adolescent psychiatrists and paediatricians in the UK. In Scotland, Child and Adolescent Mental Health Services were required to address an increase in referral rates and changes in evidence-based medicine and guidelines without additional funding. In response to this, clinicians in Dundee have, over the past 15 years, pioneered the use of integrated psychiatric, paediatric, nursing, occupational therapy, dietetic and psychological care with the development of a clearly structured, evidence-based assessment and treatment pathway to provide effective therapy for children and adolescents with ADHD. The Dundee ADHD Clinical Care Pathway (DACCP) uses standard protocols for assessment, titration and routine monitoring of clinical care and treatment outcomes, with much of the clinical work being nurse led. The DACCP has received international attention and has been used as a template for service development in many countries. This review describes the four key stages of the clinical care pathway (referral and pre-assessment; assessment, diagnosis and treatment planning; initiating treatment; and continuing care) and discusses translation of the DACCP into other healthcare systems. Tools for healthcare professionals to use or adapt according to their own clinical settings are also provided.
Appendix
Available only for authorised users
Footnotes
1
A mental health practitioner who focuses on the interface between primary and secondary care. Primary mental health workers may have a variety of professional backgrounds, including nursing, psychology, social work and education.
 
Literature
1.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–8.CrossRefPubMed
2.
3.
Ford T, Goodman R, Meltzer H. The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry. 2003;42:1203–11.CrossRefPubMed
4.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fifth Edition (DSM-5). Arlington: American Psychiatric Publishing; 2013.
5.
World Health Organization. International Classification of Diseases (ICD-10). Geneva: WHO; 1992.
6.
DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention-deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry. 2001;40:508–15.CrossRefPubMed
7.
Wehmeier PM, Schacht A, Barkley RA. Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J Adolesc Health. 2010;46:209–17.CrossRefPubMed
8.
Wilson JM, Marcotte AC. Psychosocial adjustment and educational outcome in adolescents with a childhood diagnosis of attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1996;35:579–87.CrossRefPubMed
9.
Salmon G, Kemp A. ACHD: a survey of psychiatric and paediatric practice. CAMH. 2002;7:73–8.
10.
Holden SE, Jenkins-Jones S, Poole CD, Morgan CL, Coghill D, Currie CJ. The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). Child Adolesc Psychiatry Ment Health. 2013;7:34.PubMedCentralCrossRefPubMed
11.
Langley K, Fowler T, Ford T, Thapar AK, van den Bree M, Harold G, et al. Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder. Br J Psychiatry. 2010;196:235–40.CrossRefPubMed
12.
Murray DW, Arnold LE, Swanson J, Wells K, Burns K, Jensen P, et al. A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA). Curr Psychiatry Rep. 2008;10:424–31.CrossRefPubMed
13.
MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56:1073–86.CrossRef
14.
Kovshoff H, Williams S, Vrijens M, Danckaerts M, Thompson M, Yardley L, et al. The decisions regarding ADHD management (DRAMa) study: uncertainties and complexities in assessment, diagnosis and treatment, from the clinician’s point of view. Eur Child Adolesc Psych. 2012;21:89–99.
15.
16.
17.
18.
19.
Taylor E, Sergeant J, Doepfner M, Gunning B, Overmeyer S, Mobius HJ, et al. Clinical guidelines for hyperkinetic disorder. European Society for Child and Adolescent Psychiatry. Eur Child Adolesc Psychiatry. 1998;7:184–200.CrossRefPubMed
20.
Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry. 2004;13(Suppl 1):i7–30.PubMed
21.
Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15:476–95.CrossRefPubMed
22.
Coghill D, Sergeant J. Assessment. In: Banaschewski T, Coghill D, Danckaerts M, Doepfner M, Rohde L, Sergeant JA, et al., editors. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Oxford: Oxford University Press; 2009. p. 33–51.
23.
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54:227–46.CrossRefPubMed
24.
Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011;20:17–37.PubMedCentralCrossRefPubMed
25.
Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry. 2013;170:275–89.CrossRefPubMed
26.
McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:107–25.CrossRefPubMed
27.
Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007–22.CrossRefPubMed
28.
Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:642–57.CrossRefPubMed
29.
30.
31.
NICE. Guidance on the use of methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. NICE technology appraisal guidance No 13. London, UK; 2000.
32.
Goodman R. The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry. 1997;38:581–6.CrossRefPubMed
33.
Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26:257–68.CrossRefPubMed
34.
DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV (for Children and Adolescents): checklists, norms, and clinical interpretation. New York: Guilford Publications, Inc; 1998.
35.
Swanson J, Schuck S, Mann-Porter M, Carlson C, Hartmark C, Sergeant J, et al. Categorical and dimensional definitions and evaluations of symptoms of ADHD: history of the SNAP and the SWAN rating scales. Int J Ed Psyc Assess. 2012;10:51–70.
36.
37.
Sayal K, Letch N, El Abd S. Evaluation of screening in children referred for an ADHD assessment. CAMH. 2008;13:41–6.
38.
Wigal SB, Gupta S, Guinta D, Swanson JM. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998;34:47–53.PubMed
39.
40.
Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–8.CrossRefPubMed
41.
Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, et al. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord. 1989;19:185–212.CrossRefPubMed
42.
Dunn L, Dunn L, Whetton C, Burley J. British Picture Vocabulary Scale. London: NFER-Nelson; 1997.
43.
Sonuga-Barke EJ, Daley D, Thompson M, Laver-Bradbury C, Weeks A. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. J Am Acad Child Adolesc Psychiatry. 2001;40:402–8.CrossRefPubMed
44.
Sanders MR, Turner KM, Markie-Dadds C. The development and dissemination of the Triple P-Positive Parenting Program: a multilevel, evidence-based system of parenting and family support. Prev Sci. 2002;3:173–89.CrossRefPubMed
45.
Jones K, Daley D, Hutchings J, Bywater T, Eames C. Efficacy of the Incredible Years Basic parent training programme as an early intervention for children with conduct problems and ADHD. Child Care Health Dev. 2007;33:749–56.CrossRefPubMed
46.
Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82:661–87.PubMedCentralCrossRefPubMed
47.
Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59:12–9.CrossRefPubMed
48.
Dopfner M, Steinhausen HC, Coghill D, Dalsgaard S, Poole L, Ralston SJ, et al. Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study. Eur Child Adolesc Psychiatry. 2006;15(Suppl 1):I46–55.CrossRefPubMed
49.
Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB, et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:1129–39.PubMedCentralCrossRefPubMed
50.
Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001;40:188–96.CrossRefPubMed
51.
Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. 1991;36:141–55.CrossRefPubMed
52.
Hodgkins P, Shaw M, Coghill D, Hechtman L. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012;21:477–92.PubMedCentralCrossRefPubMed
53.
Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry. 2013;13:237.PubMedCentralCrossRefPubMed
54.
55.
Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23:1208–18.CrossRefPubMed
56.
Hamilton RM, Rosenthal E, Hulpke-Wette M, Graham JG, Sergeant J. Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting. Cardiol Young. 2012;22:63–70.CrossRefPubMed
57.
58.
Achenbach T, Rescorla L. Manual for the ASEBA school-age forms and profiles; an integrated system of multi-informant assessment. Burlington: ASEBA; 2001.
59.
60.
61.
62.
Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Dopfner M, Hollis C, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19:83–105.PubMedCentralCrossRefPubMed
63.
Banaschewski T, Buitelaar J, Coghill DR, Sergeant JA, Sonuga-Barke E, Zuddas A, et al. The MTA at 8. J Am Acad Child Adolesc Psychiatry. 2009;48:1120–1.CrossRefPubMed
64.
MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1088–96.CrossRef
65.
Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): part II: supporting details. J Atten Disord. 2008;12:15–43.CrossRefPubMed
66.
Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. J Atten Disord. 2008;12:4–14.CrossRefPubMed
67.
Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK, et al. The Texas Children’s Medication Algorithm Project: report of the texas consensus conference panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part I. attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:908–19.CrossRefPubMed
68.
Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK, et al. The texas children’s medication algorithm project: report of the texas consensus conference panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part II: tactics. attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:920–7.CrossRefPubMed
69.
70.
Metadata
Title
Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway
Authors
David Coghill
Sarah Seth
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Child and Adolescent Psychiatry and Mental Health / Issue 1/2015
Electronic ISSN: 1753-2000
DOI
https://doi.org/10.1186/s13034-015-0083-2

Other articles of this Issue 1/2015

Child and Adolescent Psychiatry and Mental Health 1/2015 Go to the issue

Research

Brief report: large individual variation in outcomes of autistic children receiving low-intensity behavioral interventions in community settings

Editorial

Nonsuicidal self-injury: a rapidly evolving global field

Research article

Parenting behavior in families of female adolescents with nonsuicidal self-injury in comparison to a clinical and a nonclinical control group

Case Report

An adolescent with significant emotional and medically unexplained complaints: case report and proposal of an intervention

Research article

Parents’ perception of child and adolescent mental health problems and their choice of treatment option in southwest Ethiopia

Review

Child and adolescent psychiatry services in Singapore